Literature DB >> 15768335

Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

Brian R Edlin1, Thomas F Kresina, Daniel B Raymond, Michael R Carden, Marc N Gourevitch, Josiah D Rich, Laura W Cheever, Victoria A Cargill.   

Abstract

Injection drug use accounts for most of the incident infections with hepatitis C virus (HCV) in the United States and other developed countries. HCV infection is a complex and challenging medical condition in injection drug users (IDUs). Elements of care for hepatitis C in illicit drug users include prevention counseling and education; screening for transmission risk behavior; testing for HCV and human immunodeficiency virus infection; vaccination against hepatitis A and B viruses; evaluation for comorbidities; coordination of substance-abuse treatment services, psychiatric care, and social support; evaluation of liver disease; and interferon-based treatment for HCV infection. Caring for patients who use illicit drugs presents challenges to the health-care team that require patience, experience, and an understanding of the dynamics of substance use and addiction. Nonetheless, programs are successfully integrating hepatitis C care for IDUs into health-care settings, including primary care, methadone treatment and other substance-abuse treatment programs, infectious disease clinics, and clinics in correctional facilities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15768335      PMCID: PMC1510897          DOI: 10.1086/427441

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  109 in total

1.  Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water.

Authors:  C B McCoy; L R Metsch; D D Chitwood; P Shapshak; S T Comerford
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

2.  Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws.

Authors:  A A Gleghorn; G Gee; D Vlahov
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

3.  Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers' practices.

Authors:  L Wright-De Agüero; B Weinstein; T S Jones; J Miles
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

Review 4.  Prevention and treatment of hepatitis C in injection drug users.

Authors:  Brian R Edlin
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 5.  Interventions to enhance patient adherence to medication prescriptions: scientific review.

Authors:  Heather P McDonald; Amit X Garg; R Brian Haynes
Journal:  JAMA       Date:  2002-12-11       Impact factor: 56.272

6.  Hepatitis B vaccination among high-risk adolescents and adults--San Diego, California, 1998-2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-19       Impact factor: 17.586

7.  HIV multidisciplinary teams work: support services improve access to and retention in HIV primary care.

Authors:  R Sherer; K Stieglitz; J Narra; J Jasek; L Green; B Moore; S Shott; M Cohen
Journal:  AIDS Care       Date:  2002-08

8.  Effectiveness of interventions to improve patient compliance: a meta-analysis.

Authors:  D L Roter; J A Hall; R Merisca; B Nordstrom; D Cretin; B Svarstad
Journal:  Med Care       Date:  1998-08       Impact factor: 2.983

9.  A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

Authors:  P Hauser; J Khosla; H Aurora; J Laurin; M A Kling; J Hill; M Gulati; A J Thornton; R L Schultz; A D Valentine; C A Meyers; C D Howell
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

10.  Access to sterile syringes in Maine: pharmacy practice after the 1993 repeal of the syringe prescription law.

Authors:  P Case; G A Beckett; T S Jones
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998
View more
  68 in total

1.  Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.

Authors:  Daniel John Smyth; Duncan Webster; Lisa Barrett; Mark MacMillan; Lisa McKnight; Frank Schweiger
Journal:  Can J Gastroenterol Hepatol       Date:  2014-11

2.  The validity of reporting willingness to use a supervised injecting facility on subsequent program use among people who use injection drugs.

Authors:  Kora DeBeck; Thomas Kerr; Calvin Lai; Jane Buxton; Julio Montaner; Evan Wood
Journal:  Am J Drug Alcohol Abuse       Date:  2011-08-11       Impact factor: 3.829

3.  Barriers to accessing care in patients with chronic hepatitis C: the impact of depression.

Authors:  D M Evon; K M Simpson; D Esserman; A Verma; S Smith; M W Fried
Journal:  Aliment Pharmacol Ther       Date:  2010-09-17       Impact factor: 8.171

4.  Written in response to Scott LD: treating hepatitis C in active injection drug users.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Am J Gastroenterol       Date:  2005-09       Impact factor: 10.864

5.  Injection drug users: the overlooked core of the hepatitis C epidemic.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

6.  Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.

Authors:  Angelique Myles; Gerry J Mugford; Jing Zhao; Murray Krahn; Peizhong P Wang
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

7.  Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report.

Authors:  Alice Asher; Paula J Lum; Kimberly Page
Journal:  J Assoc Nurses AIDS Care       Date:  2011-04-15       Impact factor: 1.354

8.  Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?

Authors:  Benedikt Fischer; Kate Kalousek; Jürgen Rehm; Jeff Powis; Mel Krajden; Jens Reimer
Journal:  Can J Public Health       Date:  2006 Nov-Dec

9.  Managing chronic hepatitis C in primary-care settings: more than antiviral therapy.

Authors:  Barry Zevin
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

10.  Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.

Authors:  Melissa R Stein; Irene J Soloway; Karen S Jefferson; Robert J Roose; Julia H Arnsten; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.